FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	IN BENEFICIAL	<b>OWNERSHIP</b>

OMB A	PPROVAL					
OMB Number:	3235-0287					
Estimated average burden						
hours per respon						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  BERMAN RICHARD J				2. Issuer Name <b>and</b> Ticker or Trading Symbol Caladrius Biosciences, Inc. [ CLBS ]									elationship eck all appli C Directo	cable)	g Pers	son(s) to Iss 10% Ov			
(Last)	,	irst) BIOSCIENCES,	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 01/09/2017							-	Officer (give title below)		Other (sp below)		pecify	
106 ALL	EN ROAD																		
(Street) BASKIN RIDGE	NG N.	J	07920		-   4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	Individual or Joint/Group Filing (Check Applicable ne)  X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(S	tate)	(Zip)																
		Tab	le I - Noi	n-Deriv	ative	Se	curitie	s Ac	quired,	Dis	osed c	of, or B	enef	iciall	y Owned	t			
Dat		Date	th/Day/Year) i		2A. Deemed Execution Date, if any (Month/Day/Year		, Transaction Disposed Code (Instr. 5)		ities Acqu d Of (D) (Ir				es Fo ially (D) Following (I)		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership			
								Code	v	Amount	(A) or (D)		rice		action(s) . 3 and 4)			(Instr. 4)	
Common Stock 01/09			9/2017	/2017		A		1,650	650 <sup>(1)</sup> A		\$0	7,177(2)			D				
		7	able II -						uired, D , option						Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Conversion Date (Month/Day/Year) Price of Derivative				action (Instr.	n of		6. Date Exercisable at Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		urity	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial ) Ownership ct (Instr. 4)
					Code	v	(A)		Date Exercisabl		xpiration ate	Title	or	ount nber ires	ber				
Options to Purchase Common	\$3.54	01/09/2017			A		2,750		01/09/2018	3 0:	1/09/2027	Common Stock	2,7	750	\$0	2,750		D	

## Explanation of Responses:

- $1.\ Represents\ 1,650\ shares\ of\ restricted\ stock\ granted\ under\ the\ Issuer's\ 2015\ Equity\ Compensation\ Plan\ that\ will\ vest\ on\ January\ 9,\ 2018.$
- $2.\ Includes\ 2,775\ shares\ of\ unvested\ restricted\ stock\ granted\ under\ the\ Issuer's\ compensation\ plans.$

Richard Berman, By: /s/ Todd

C. Girolamo, Esq., Attorney-

<u>in-Fact</u>

\*\* Signature of Reporting Person Date

01/31/2017

 $Reminder: Report \ on \ a \ separate \ line \ for \ each \ class \ of \ securities \ beneficially \ owned \ directly \ or \ indirectly.$ 

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.